Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Lepu Biopharma Co Ltd
2157Current price
3.07 HKD
0 HKD (0.00%)
Last closed
3.01 HKD
Company
www.lepubiopharma.com
ISIN
CNE100004SM4
Sector
Healthcare
Industry
Biotechnology
Exchange
Hong Kong Stock Exchange
Capitalization
5 273 710 491 HKD
Yield for 12 month
-21.68 %
1Y
3Y
5Y
10Y
15Y
2157
Lepu Biopharma Co., Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for cancer targeted therapy and immunotherapy in China and internationally. The company offers PUYOUHENG (Pucotenlimab Injection), a humanized IgG4 mAb against human PD-1 for the treatment of solid tumors and melanoma. It is also developing MRG003 that is in phase III clinical study for treating nasopharyngeal cancer, and head and neck squamous cell carcinoma; and MRG002, which is in phase III trials to treat breast and urothelial cancer, as well as HER2-positive. In addition, the company is developing MRG001 CD20-targeted ADC for treating non-Hodgkin's lymphoma; CMG901 CLDN18.2-targeted ADC for treating gastric and gastroesophageal junction carcinoma and other solid tumors; and MRG004A TF-targeted ADC for treating advanced or metastatic solid tumors. Further, it is developing CG00705 Oncolytic virus for treating bacillus calmette-guerin unresponsive non-muscle invasive bladder cancer; and MRG006A and CTM012 for the treatment of solid tumors. The company was incorporated in 2018 and is headquartered in Shanghai, China. Address: No. 651, Lianheng Road, Shanghai, China, 201612
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
38.81 HKDP/E ratio
–Dividend Yield
–Current Year
+225 566 393 HKD
Last Year
+15 586 816 HKD
Current Quarter
+153 699 084 HKD
Last Quarter
–
Current Year
+197 262 488 HKD
Last Year
+13 579 906 HKD
Current Quarter
+147 938 605 HKD
Last Quarter
–
Key Figures 2157
1 year
3 years
5 years
10 years
EBITDA
-368 152 918 HKD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-11.33 %
PEG Ratio
–
Return On Equity TTM
-10.26 %
Wall Street Target Price
38.81 HKD
Revenue TTM
205 277 105 HKD
Book Value
0.54 HKD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-13.2 %
Dividend Yield
–
Gross Profit TTM
13 579 907 HKD
Earnings per share
–
Diluted Eps TTM
–
Most Recent Quarter
II 2023
Quarterly Earnings Growth YOY
–
Profit Margin
-35.41 %
Dividend Analytics 2157
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History 2157
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation 2157
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
24.6841
Price Sales TTM
25.6907
Enterprise Value EBITDA
66.5551
Price Book MRQ
5.318
Financials 2157
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators 2157
For 52 weeks
2.16 HKD
6.51 HKD
50 Day MA
3.03 HKD
Shares Short Prior Month
–
200 Day MA
3.62 HKD
Short Ratio
–
Shares Short
–
Short Percent
–
BeatStart